FDA Green Light: CASI Drug Aims at Leading Cause of Kidney Transplant Failure

China based CASI Pharmaceuticals (NASDAQ:CASI) has received FDA clearance for its Investigational New Drug (IND) application for CID-103, a potential best-in-class anti-CD38 monoclonal antibody targeting renal allograft antibody-mediated rejection (AMR). The company plans to initiate a Phase 1 clinical trial to evaluate the safety, tolerability, and efficacy of CID-103 in adults with active and chronic active renal allograft AMR.

AMR is identified as a leading cause of kidney transplant failure, often resulting in dialysis or repeat transplantation. The Phase 1 study will focus on dose-ranging and safety assessments, addressing an urgent medical need in transplant medicine where current treatment options are limited.

https://www.stocktitan.net/news/CASI/casi-pharmaceuticals-announces-fda-clearance-of-ind-application-for-y38zmno03hya.html